Amgen (AMGN) Goodwill & Intangibles (2009 - 2026)
Amgen (AMGN) recorded quarterly Goodwill & Intangibles of $40.1 billion in Q1 2026, down 2.2% quarter-over-quarter from $41.0 billion in Q4 2025, and up 70.84% on a YoY basis from $23.4 billion in Q1 2025.
Amgen (AMGN) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Amgen's Goodwill & Intangibles history runs 18 years deep, the most recent figure standing at $40.1 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 70.84% year-over-year to $40.1 billion; the TTM figure through Mar 2026 stood at $40.1 billion (up 70.84% YoY), while the FY2025 annual figure was $41.0 billion, down 11.61% from the prior year.
- Goodwill & Intangibles was $40.1 billion for Q1 2026 at Amgen, down from $41.0 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $51.3 billion in Q4 2023 to a low of $19.0 billion in Q2 2025.
- Historically, Goodwill & Intangibles has averaged $36.3 billion across 5 years, with a median of $31.6 billion in 2022.
- The sharpest annual moves came in 2025 and 2026: Goodwill & Intangibles sank 61.01% in 2025, then jumped 70.84% in 2026.
- A 5-year view of Goodwill & Intangibles shows it stood at $31.6 billion in 2022, then soared by 62.2% to $51.3 billion in 2023, then retreated by 9.62% to $46.3 billion in 2024, then retreated by 11.61% to $41.0 billion in 2025, then decreased by 2.2% to $40.1 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $40.1 billion (Q1 2026), $41.0 billion (Q4 2025), and $41.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.05 Bn |
| Dec 31, 2025 | 40.96 Bn |
| Sep 30, 2025 | 41.82 Bn |
| Jun 30, 2025 | 19.02 Bn |
| Mar 31, 2025 | 23.45 Bn |
| Dec 31, 2024 | 46.34 Bn |
| Sep 30, 2024 | 47.58 Bn |
| Jun 30, 2024 | 48.79 Bn |
| Mar 31, 2024 | 49.94 Bn |
| Dec 31, 2023 | 51.27 Bn |
| Sep 30, 2023 | 28.66 Bn |
| Jun 30, 2023 | 30.16 Bn |
| Mar 31, 2023 | 30.92 Bn |
| Dec 31, 2022 | 31.61 Bn |
| Sep 30, 2022 | 28.11 Bn |
| Jun 30, 2022 | 28.79 Bn |
| Mar 31, 2022 | 29.46 Bn |
| Dec 31, 2021 | 30.07 Bn |
| Sep 30, 2021 | 29.32 Bn |
| Jun 30, 2021 | 29.98 Bn |